Glomerular Endothelial Rarefaction Associated With Hypoxic Neutrophils Marks Renal Pathology Activity in Lupus Nephritis
Arthritis & Rheumatology · 09.06.2026
DOI: 10.1002/art.70220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 09.06.2026. Verfasst von Anto Sam Crosslee Louis Sam Titus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering Department, University of Houston, Houston, Texas. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
This study aims to investigate the spatial transcriptomics of hypoxia and immune‐mediated damage within renal tissue in patients with lupus nephritis (LN) in comparison to healthy controls from kidney transplants.
Methods
Renal biopsies from patients with LN and transplant controls were imaged using multiplexed cyclic immunofluorescence to spatially quantify immune and endothelial cell markers. An independent LN cohort of patients underwent Visium spatial transcriptomics analysis. Hypoxia was modeled in cell lines and primary neutrophils using cobalt chloride, and urinary neutrophil cargo proteins were measured using an enzyme‐linked immunosorbent assay.
Results
LN glomeruli exhibited increased HIF‐1α–expressing CD68 + macrophages and CD66 + neutrophils along with diffuse perinuclear staining for myeloperoxidase (MPO), indicative of heightened NETosis and N2 reparative neutrophil presence. Spatial transcriptomic analysis confirmed the correlation between glomerular hypoxia and neutrophil extracellular trap (NET) formation. The renal pathology activity index was highly correlated with hypoxic neutrophil count, and these parameters correlated with glomerular endothelial rarefaction and reduced capillary lengths, junctions, and branching. Urinary neutrophil cargo and NET proteins (MPO and proteinase 3) were also elevated in active LN.
Conclusion
We posit that glomerular endothelial cell damage leads to hypoxia in LN, resulting in hypoxic, reparative myeloid cells and NETosis, whereas the latter has been linked to downstream inflammation and in situ trapping of antinuclear antibodies in LN. These glomerular events underpin high renal pathology activity and may pave the path toward irreversible damage in LN. Detection of neutrophil cargo in urine supports the potential for a liquid biopsy to monitor disease progression.
Autor:innen und Institutionen
- Biomedical Engineering Department, University of Houston, Houston, Texas.
- Immunotherapy Research Center, Houston Methodist Research Institute, Houston, Texas.
- Department of Internal Medicine, Division of Nephrology, UT Southwestern Medical Center, Dallas, Texas.
- Department of Pathology, UT Southwestern Medical Center, Dallas, Texas.
- Department of Pathology, Houston Methodist Hospital, Houston, Texas.
ORCID-Profile: Anto Sam Crosslee Louis Sam Titus, Aalekhya Biswas
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Louis Sam Titus, A. S. C., Biswas, A., Srinivasan, V., Surya, V., Appalaneni, R., Chen, S. H., Saxena, R., Cai, Q., Truong, L., & Mohan, C. (2026). Glomerular Endothelial Rarefaction Associated With Hypoxic Neutrophils Marks Renal Pathology Activity in Lupus Nephritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70220
Vancouver
Louis Sam Titus ASC, Biswas A, Srinivasan V, Surya V, Appalaneni R, Chen SH, et al. Glomerular Endothelial Rarefaction Associated With Hypoxic Neutrophils Marks Renal Pathology Activity in Lupus Nephritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70220
BibTeX
@article{LouisSamTitus2026,
author = {Louis Sam Titus, Anto Sam Crosslee and Biswas, Aalekhya and Srinivasan, Vishal and Surya, Vishal and Appalaneni, Rohith and Chen, Shu-Hsia and Saxena, Ramesh and Cai, Qi and Truong, Luan and Mohan, Chandra},
title = {Glomerular Endothelial Rarefaction Associated With Hypoxic Neutrophils Marks Renal Pathology Activity in Lupus Nephritis},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70220}
}
EUVIMED